Huyabio International SHP2 EGFR Combination Therapy Patent EP4334317A1
Summary
Huyabio International, LLC obtained EPO Publication EP4334317A1 on April 15, 2026, covering combination therapies comprising SHP2 inhibitors and EGFR tyrosine kinase kinase inhibitors for cancer treatment. The patent application was filed with IPC classifications including A61K31/519, C07D471/04, and A61P35/00, and designates all EU member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR. Inventors include SHOJAEI Farbod, RICONO Jill M., GOODENOW Robert, and GILLINGS Mireille.
“COMBINATION THERAPIES COMPRISING SHP2 INHIBITORS AND EGFR TYROSINE KINASE INHIBITORS”
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 63 changes logged to date.
What changed
The EPO published Huyabio International, LLC's patent application EP4334317A1 covering combination therapies comprising SHP2 inhibitors and EGFR tyrosine kinase inhibitors for cancer treatment. The application includes claims under multiple IPC classifications including A61K31/519, C07D471/04, C07D401/14, C07D403/14, and C07D487/04, with designations extending to all EU member states. Inventors listed include SHOJAEI Farbod, RICONO Jill M., GOODENOW Robert, and GILLINGS Mireille.
Pharmaceutical and biotechnology companies developing targeted cancer therapies should review this publication for potential freedom-to-operate considerations, particularly those with programs involving SHP2 or EGFR pathways. Competitors with overlapping research in combination oncology therapies may wish to evaluate the scope of claims for potential licensing discussions or inter partes review proceedings.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMBINATION THERAPIES COMPRISING SHP2 INHIBITORS AND EGFR TYROSINE KINASE INHIBITORS
Publication EP4334317A1 Kind: A1 Apr 15, 2026
Applicants
Huyabio International, LLC
Inventors
SHOJAEI, Farbod, RICONO, Jill M., GOODENOW, Robert, GILLINGS, Mireille
IPC Classifications
A61K 31/519 20060101AFI20250127BHEP A61K 31/506 20060101ALI20250127BHEP A61P 35/00 20060101ALI20250127BHEP C07D 471/04 20060101ALI20250127BHEP C07D 401/14 20060101ALI20250127BHEP C07D 403/14 20060101ALI20250127BHEP C07D 487/04 20060101ALI20250127BHEP A61K 45/06 20060101ALI20250127BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.